Cargando…

Low-Concentration Atropine Monotherapy vs. Combined with MiSight 1 Day Contact Lenses for Myopia Management

Objectives: To assess the decrease in myopia progression and rebound effect using topical low-dose atropine compared to a combined treatment with contact lenses for myopic control. Methods: This retrospective review study included 85 children aged 10.34 ± 2.27 (range 6 to 15.5) who were followed ove...

Descripción completa

Detalles Bibliográficos
Autores principales: Erdinest, Nir, London, Naomi, Lavy, Itay, Landau, David, Ben Ephraim Noyman, Dror, Levinger, Nadav, Morad, Yair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781043/
https://www.ncbi.nlm.nih.gov/pubmed/36548935
http://dx.doi.org/10.3390/vision6040073
_version_ 1784856977031036928
author Erdinest, Nir
London, Naomi
Lavy, Itay
Landau, David
Ben Ephraim Noyman, Dror
Levinger, Nadav
Morad, Yair
author_facet Erdinest, Nir
London, Naomi
Lavy, Itay
Landau, David
Ben Ephraim Noyman, Dror
Levinger, Nadav
Morad, Yair
author_sort Erdinest, Nir
collection PubMed
description Objectives: To assess the decrease in myopia progression and rebound effect using topical low-dose atropine compared to a combined treatment with contact lenses for myopic control. Methods: This retrospective review study included 85 children aged 10.34 ± 2.27 (range 6 to 15.5) who were followed over three years. All had a minimum myopia increase of 1.00 D the year prior to treatment. The children were divided into two treatment groups and a control group. One treatment group included 29 children with an average prescription of 4.81 ± 2.12 D (sphere equivalent (SE) range of 1.25–10.87 D), treated with 0.01% atropine for two years (A0.01%). The second group included 26 children with an average prescription of 4.14 ± 1.35 D (SE range of 1.625–6.00 D), treated with MiSight 1 day dual focus contact lenses (DFCL) and 0.01% atropine (A0.01% + DFCL) for two years. The control group included 30 children wearing single-vision spectacles (SV), averaging −5.06 ± 1.77 D (SE) range 2.37–8.87 D). Results: There was an increase in the SE myopia progression in the SV group of 1.19 ± 0.43 D, 1.25 ± 0.52 D, and 1.13 ± 0.36 D in the first, second, and third years, respectively. Myopia progression in the A0.01% group was 0.44 ± 0.21 D (p < 0.01) and 0.51 ± 0.39 D (p < 0.01) in the first and second years, respectively. In the A0.01% + DFCL group, myopia progression was 0.35 ± 0.26 D and 0.44 ± 0.40 D in the first and second years, respectively (p < 0.01). Half a year after the cessation of the atropine treatment, myopia progression (rebound effect) was measured at −0.241 ± 0.35 D and −0.178 ± 0.34 D in the A0.01% and A0.01% + DFCL groups, respectively. Conclusions: Monotherapy low-dose atropine, combined with peripheral blur contact lenses, was clinically effective in decreasing myopia progression. A low rebound effect was found after the therapy cessation. In this retrospective study, combination therapy did not present an advantage over monotherapy.
format Online
Article
Text
id pubmed-9781043
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97810432022-12-24 Low-Concentration Atropine Monotherapy vs. Combined with MiSight 1 Day Contact Lenses for Myopia Management Erdinest, Nir London, Naomi Lavy, Itay Landau, David Ben Ephraim Noyman, Dror Levinger, Nadav Morad, Yair Vision (Basel) Article Objectives: To assess the decrease in myopia progression and rebound effect using topical low-dose atropine compared to a combined treatment with contact lenses for myopic control. Methods: This retrospective review study included 85 children aged 10.34 ± 2.27 (range 6 to 15.5) who were followed over three years. All had a minimum myopia increase of 1.00 D the year prior to treatment. The children were divided into two treatment groups and a control group. One treatment group included 29 children with an average prescription of 4.81 ± 2.12 D (sphere equivalent (SE) range of 1.25–10.87 D), treated with 0.01% atropine for two years (A0.01%). The second group included 26 children with an average prescription of 4.14 ± 1.35 D (SE range of 1.625–6.00 D), treated with MiSight 1 day dual focus contact lenses (DFCL) and 0.01% atropine (A0.01% + DFCL) for two years. The control group included 30 children wearing single-vision spectacles (SV), averaging −5.06 ± 1.77 D (SE) range 2.37–8.87 D). Results: There was an increase in the SE myopia progression in the SV group of 1.19 ± 0.43 D, 1.25 ± 0.52 D, and 1.13 ± 0.36 D in the first, second, and third years, respectively. Myopia progression in the A0.01% group was 0.44 ± 0.21 D (p < 0.01) and 0.51 ± 0.39 D (p < 0.01) in the first and second years, respectively. In the A0.01% + DFCL group, myopia progression was 0.35 ± 0.26 D and 0.44 ± 0.40 D in the first and second years, respectively (p < 0.01). Half a year after the cessation of the atropine treatment, myopia progression (rebound effect) was measured at −0.241 ± 0.35 D and −0.178 ± 0.34 D in the A0.01% and A0.01% + DFCL groups, respectively. Conclusions: Monotherapy low-dose atropine, combined with peripheral blur contact lenses, was clinically effective in decreasing myopia progression. A low rebound effect was found after the therapy cessation. In this retrospective study, combination therapy did not present an advantage over monotherapy. MDPI 2022-12-12 /pmc/articles/PMC9781043/ /pubmed/36548935 http://dx.doi.org/10.3390/vision6040073 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Erdinest, Nir
London, Naomi
Lavy, Itay
Landau, David
Ben Ephraim Noyman, Dror
Levinger, Nadav
Morad, Yair
Low-Concentration Atropine Monotherapy vs. Combined with MiSight 1 Day Contact Lenses for Myopia Management
title Low-Concentration Atropine Monotherapy vs. Combined with MiSight 1 Day Contact Lenses for Myopia Management
title_full Low-Concentration Atropine Monotherapy vs. Combined with MiSight 1 Day Contact Lenses for Myopia Management
title_fullStr Low-Concentration Atropine Monotherapy vs. Combined with MiSight 1 Day Contact Lenses for Myopia Management
title_full_unstemmed Low-Concentration Atropine Monotherapy vs. Combined with MiSight 1 Day Contact Lenses for Myopia Management
title_short Low-Concentration Atropine Monotherapy vs. Combined with MiSight 1 Day Contact Lenses for Myopia Management
title_sort low-concentration atropine monotherapy vs. combined with misight 1 day contact lenses for myopia management
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781043/
https://www.ncbi.nlm.nih.gov/pubmed/36548935
http://dx.doi.org/10.3390/vision6040073
work_keys_str_mv AT erdinestnir lowconcentrationatropinemonotherapyvscombinedwithmisight1daycontactlensesformyopiamanagement
AT londonnaomi lowconcentrationatropinemonotherapyvscombinedwithmisight1daycontactlensesformyopiamanagement
AT lavyitay lowconcentrationatropinemonotherapyvscombinedwithmisight1daycontactlensesformyopiamanagement
AT landaudavid lowconcentrationatropinemonotherapyvscombinedwithmisight1daycontactlensesformyopiamanagement
AT benephraimnoymandror lowconcentrationatropinemonotherapyvscombinedwithmisight1daycontactlensesformyopiamanagement
AT levingernadav lowconcentrationatropinemonotherapyvscombinedwithmisight1daycontactlensesformyopiamanagement
AT moradyair lowconcentrationatropinemonotherapyvscombinedwithmisight1daycontactlensesformyopiamanagement